Directorio

Participants will be randomly assigned to receive either standard treatment after surgery or standard treatment plus an additional radiation treatment called I²-PORT. Standard treatment may include chemotherapy, immunotherapy, or no further treatment, depending on the participant’s medical care plan. Researchers will compare the two approaches to see if adding I²-PORT improves outcomes for people with non-small cell lung cancer.

The ALPINE study wants to find out if a medicine called brepocitinib can help control a condition called lichen planopilaris. The medicine is a pill that people take once each day. The study will also compare how well the medicine works when compared to a placebo, which is a pill that has no medicine in it.

In this study, you will take a medicine called ALTA3263 by mouth every day. You will keep taking it until your cancer gets worse or until you need to stop because of strong or frequent side effects. While you are in the study, you will go to the clinic for regular visits. During these visits, the study team will do tests to check your health and collect information for research.

In this study, all participants will receive a study medicine called xaluritamig through a tube placed in a vein. Each treatment takes about one hour. At the start, lower doses are given every two weeks. Later, treatments are given every four weeks. Before starting, you will have tests such as blood work, scans, and a physical exam to make sure you can join the study. During the study, you will have regular clinic visits for treatments, checkups, blood tests, and scans like CT or MRI to watch your health and your cancer. Early in treatment, you may need to stay at the clinic or hospital for a short time after the medicine is given so doctors can monitor you. You will also need a caregiver to help you for a short time after treatment. You can keep receiving the medicine as long as it is helping you, and doctors will continue to check on you for up to about two years.

In this study, people will be placed into one of two groups by chance. One group will receive two medicines, called romiplostim and prednisone. The other group will receive only prednisone, which is the usual treatment. During the first part of the study, people in the study treatment group will receive weekly shots of romiplostim for up to 24 weeks and take prednisone for up to 8 weeks. People in the usual treatment group will take prednisone for up to 8 weeks. After 24 weeks, everyone will move to the second part of the study. The study treatment group may continue receiving romiplostim for up to one year, while the usual treatment group will not receive the study medicine. Throughout the study, participants will visit the clinic for blood tests and physical exams so doctors can check their health and see how well the treatment is working.

We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.